Navigation Links
Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
Date:4/14/2011

nutes following a bolus infusion was 64% greater for the Aspart-PH20 formulation compared to aspart alone (p < 0.0001). Insulin exposure beyond 2 hours after the bolus decreased by 42% for the combination compared to aspart alone (p = 0.0003). These results clearly demonstrate the faster-in/faster-out pharmacokinetic (PK) profile for the combination Aspart-PH20. The faster PK also translated into accelerated insulin action for the combination treatment. As demonstrated with a euglycemic clamp procedure, Aspart-PH20 action in the first 2 hours was 20% greater relative to aspart alone (p = 0.047) with 37% less insulin action beyond 4 hours after injection (p = 0.008). These results have been obtained for the first 13 patients and enrollment of an additional 5 patients is continuing for the aspart stage of the study. So far, the overall safety and adverse event profiles for Aspart-PH20 and aspart alone were comparable and both treatments were well tolerated. Additional parameters important for pump use are being tested, with data available later in 2011.

The goal of Halozyme's Ultrafast Insulin program is to develop a best-in-class mealtime insulin product compared to the currently prescribed analogs that participate in the growing $3.8 billion worldwide prandial insulin market. Additional information about Halozyme's on-going Ultrafast Insulin trials can be found at clinicaltrials.gov using the identifiers NCT01275131, NCT01194245 and NCT01194258.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanz
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ultrafast laser scribing technique to cut cost, hike efficiency of solar cells
2. Short, on-chip light pulses will enable ultrafast data transfer within computers
3. Ultrafast lasers give CU-Boulder researchers a snapshot of electrons in action
4. Structured Diabetes Management can Significantly Improve Overall Glycemic Control and Reduce HbA1c Values in Non-insulin Treated Type 2 Diabetes
5. Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
6. Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin
7. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
8. Tosoh Bioscience Introduces TSK-GEL SP-3PW (30), a Higher-Capacity Resin for the Purification of Insulin and Other Therapeutic Peptides and Small Proteins
9. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
10. Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil
11. Biolaxy Secures IND Approval for Oral Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... synthetic biology covers the designing and engineering of completely ... the redesigning of natural biological systems that provide improved ... form of extreme genetic engineering because it not only ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Immunomic Therapeutics, ... researchers to further develop potential treatments for glioblastoma multiforme ... in combination with their patented vaccine platform, LAMP-vax. ... University, are based on the work of John H. ... at The Preston Robert Tisch Brain Tumor Center at ...
(Date:7/28/2014)... Appistry, Inc. , a leading provider ... of genomics to next-generation medicine, announced today its judging ... , Two Appistry staff will be joined by ... Genome Resources, and Mr. Neil Miller, director of informatics ... Rounding out the panel are Appistry’s Dr. Richard Mazzarella, ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... SOUTH SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, ... advances in cardiovascular disease, inflammatory disease,and cancer, today ... of novel,compounds that inhibit spleen tyrosine kinase (Syk) ... be presented at the annual meeting of the,American ...
... Medarex, Inc.,(Nasdaq: MEDX ) announced today that it ... 3:30 p.m. Eastern Time on Wednesday,December 10, 2008. The event will ... of the Medarex website at www.medarex.com . An,archived edition of ... About Medarex , ...
... markets, the trend in health care employment could be counted on ... bringing yearly growth up over 345,000.The MedZilla.com Employment Report analyzes the ... ... Seattle, WA (Vocus) December 3, 2008 -- The U.S. economy ...
Cached Biology Technology:Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 3
(Date:7/28/2014)... RENO Norwegian explorer Roald Amundsen became the first ... 1911. More than 100 years later, an international team ... Research Institute (DRI) have proven that air pollution from ... 16 ice cores collected from widely spaced locations around ... created the most accurate and precise reconstruction to date ...
(Date:7/27/2014)... survived the asteroid strike that wiped them out if ... history, scientists say. , A fresh study using up-to-date ... to build a new narrative of the prehistoric creatures, ... that in the few million years before a 10km-wide ... environmental upheaval. This included extensive volcanic activity, changing sea ...
(Date:7/27/2014)... a new species of mayfly in the southern Western Ghats, ... fact, this is the first time that any mayfly belonging ... peninsular India. , The new species, called Labiobaetis soldani ... his substantial contribution to the understanding of the Ephemeroptera of ... study that describes the new mayfly in the Journal ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... 23andMe, the leading personal genetics company, announces the ... Neil Rothstein as Vice President Marketing, and Jonathan ... company,s executive leadership team. As ... the company,s corporate communications, media relations and investor ...
... Oct. 17, 2012 Rising crime rates and ... increase monitoring and introduce reliable border control systems. ... criminal identification and automated immigration at all entry ... adoption in the government vertical across Asia-Pacific. ...
... 24, 2012  Aware, Inc. (NASDAQ: AWRE ), ... assurance products, today reported financial results for its third ... our DSL service assurance hardware business have been reported ... the shutdown of that business during the third quarter. ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... standard for whole-blood clinical diagnostic work in ... less, this analyzer makes precise glucose measurements ... precise lactate measurements of whole blood, plasma, ... option allows you to have glucose results ...
... The first high-density serum biomarker chip to ... proteins. An antibody chip containing 120 human ... that enables biomarker discovery scientists to study ... benefits of therapy and the likelihood of ...
... description: The Costar strip ejector is a ... of Costar strips from their holder. Linkage: ... number, created to easily match Cornings product ... order under the old Sigma-Aldrich number (Z71,314-7) ...
Biology Products: